应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
LGND Ligand Pharmaceuticals Inc.
盘后交易 12-16 17:02:07 EST
192.63
-0.25
-0.13%
盘后
192.63
+0.00
0.00%
16:20 EST
最高
196.00
最低
188.69
成交量
21.90万
今开
191.68
昨收
192.88
日振幅
3.79%
总市值
37.91亿
流通市值
36.92亿
总股本
1,968万
成交额
4,221万
换手率
1.14%
流通股本
1,916万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Ligand Pharmaceuticals Incorporated涨0.80% 股价突破200美元大关
市场透视 · 11-24
Ligand Pharmaceuticals Incorporated涨0.80% 股价突破200美元大关
Ligand Pharmaceuticals第三季度每股收益为5.68美元
投资观察 · 11-20
Ligand Pharmaceuticals第三季度每股收益为5.68美元
历史数据显示,下周这些美股公司公布的财报往往会超出预期
老虎资讯综合 · 10-31
历史数据显示,下周这些美股公司公布的财报往往会超出预期
Ligand Pharmaceuticals合作伙伴Sq Innovation获得FDA批准,推出用于心衰患者水肿居家治疗的Lasix® Onyu
美股速递 · 10-09
Ligand Pharmaceuticals合作伙伴Sq Innovation获得FDA批准,推出用于心衰患者水肿居家治疗的Lasix® Onyu
ARECOR THERAPEUTICS PLC宣布与Ligand Pharmaceuticals Inc.达成版税融资协议,筹资上限达1100万美元且不摊薄股权
美股速递 · 09-25
ARECOR THERAPEUTICS PLC宣布与Ligand Pharmaceuticals Inc.达成版税融资协议,筹资上限达1100万美元且不摊薄股权
异动解读 | 利根制药股价盘中大涨5.29%,4亿美元可转债发行引发投资者热情
异动解读 · 08-12
异动解读 | 利根制药股价盘中大涨5.29%,4亿美元可转债发行引发投资者热情
异动解读 | Ligand Pharmaceuticals盘中大跌8%,拟发行4亿美元可转债
异动解读 · 08-11
异动解读 | Ligand Pharmaceuticals盘中大跌8%,拟发行4亿美元可转债
Ligand Pharmaceuticals Incorporated盘中异动 急速下挫6.79%
市场透视 · 08-11
Ligand Pharmaceuticals Incorporated盘中异动 急速下挫6.79%
Ligand Pharmaceuticals Incorporated盘中异动 股价大涨5.08%报142.01美元
市场透视 · 08-07
Ligand Pharmaceuticals Incorporated盘中异动 股价大涨5.08%报142.01美元
Ligand Pharmaceuticals Incorporated盘中异动 股价大涨5.25%报130.82美元
市场透视 · 07-16
Ligand Pharmaceuticals Incorporated盘中异动 股价大涨5.25%报130.82美元
Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.68%
市场透视 · 07-09
Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.68%
Ligand Pharmaceuticals Incorporated盘中异动 急速下跌5.12%
市场透视 · 03-10
Ligand Pharmaceuticals Incorporated盘中异动 急速下跌5.12%
Ligand Pharmaceuticals Incorporated2024财年实现净利润-4.03百万美元,同比减少107.49%
市场透视 · 03-08
Ligand Pharmaceuticals Incorporated2024财年实现净利润-4.03百万美元,同比减少107.49%
Ligand Pharmaceuticals Incorporated盘中异动 股价大跌5.06%报116.05美元
市场透视 · 03-03
Ligand Pharmaceuticals Incorporated盘中异动 股价大跌5.06%报116.05美元
异动解读 | Ligand Pharmaceuticals盘中股价剧涨5.07% 公司业绩表现亮眼
异动解读 · 03-01
异动解读 | Ligand Pharmaceuticals盘中股价剧涨5.07% 公司业绩表现亮眼
Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.07%报121.54美元
市场透视 · 03-01
Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.07%报121.54美元
异动解读 | LGND 2024年Q4财报超预期,股价盘中大涨6.32%
异动解读 · 02-27
异动解读 | LGND 2024年Q4财报超预期,股价盘中大涨6.32%
Ligand Pharmaceuticals Incorporated盘中异动 大幅上涨5.18%
市场透视 · 02-27
Ligand Pharmaceuticals Incorporated盘中异动 大幅上涨5.18%
Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19,销售额$4281万 超过预估的$3902万
财报速递 · 02-27
Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19,销售额$4281万 超过预估的$3902万
Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.22%
市场透视 · 02-15
Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.22%
加载更多
公司概况
公司名称:
Ligand Pharmaceuticals Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Ligand Pharmaceuticals Incorporated于1987年在特拉华州注册,是一家生物制药公司。公司商业模式为,开发或收购能产生收益的资产,将其融合到精益企业的成本结构中。公司的目标是创造可持续盈利的业务以生成股东价值。由于公司的商业模式是基于与其他制药公司合作,商业化利用并销售资产,因此公司不少收入来自合作伙伴提供的相关使用费。公司认识到了制药行业药物重制的重要性,2011年将CAPTISOL项目加入到技术投资中。CAPTISOL是一个功能强大的配方技术,拥有5个美国食品药品管理局批准的产品,包括Pfizer公司的VFEND IV和Baxter International公司的Nexterone,以及其他一些在临床阶段投入使用的合作伙伴项目。与同行的其他公司相比,公司已经组建了一个最大的行业多元化资产组合,在未来能产生显著的收益。资产组合中发展的治疗方案可以解决许多尚未得到解决的医疗需求缺口,包括肝炎、肌肉萎缩、老年痴呆症、血脂异常、糖尿病、贫血、哮喘、类风湿关节炎、和骨质疏松症。
发行价格:
--
{"stockData":{"symbol":"LGND","market":"US","secType":"STK","nameCN":"Ligand Pharmaceuticals Inc.","latestPrice":192.63,"timestamp":1765918800000,"preClose":192.88,"halted":0,"volume":219044,"hourTrading":{"tag":"盘后","latestPrice":192.63,"preClose":192.63,"latestTime":"16:20 EST","volume":8380,"amount":1614239.4,"timestamp":1765920000492},"delay":0,"floatShares":19164275,"shares":19681720,"eps":2.49036,"marketStatus":"盘后交易","change":-0.25,"latestTime":"12-16 17:02:07 EST","open":191.68,"high":196,"low":188.69,"amount":42207301.41236,"amplitude":0.037899,"askPrice":194.65,"askSize":2,"bidPrice":188.91,"bidSize":10,"shortable":3,"etf":0,"ttmEps":2.49036,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765933200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":721976400000,"exchange":"NASDAQ","adjPreClose":192.88,"postHourTrading":{"tag":"盘后","latestPrice":192.63,"preClose":192.63,"latestTime":"16:20 EST","volume":8380,"amount":1614239.4,"timestamp":1765920000492},"volumeRatio":0.931649,"impliedVol":0.3042,"impliedVolPercentile":0.124},"requestUrl":"/m/hq/s/LGND","defaultTab":"news","newsList":[{"id":"2586473612","title":"Ligand Pharmaceuticals Incorporated涨0.80% 股价突破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473612","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473612?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:33","pubTimestamp":1763994806,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时33分,Ligand Pharmaceuticals Incorporated股票出现异动,股价急速上涨0.80%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为0.35%。其相关个股中,Pasithea Therapeutics Corp C/Wts 12/08/2026 、Enlivex Therapeutics Ltd.、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大,Enlivex Therapeutics Ltd.、Pasithea Therapeutics Corp.、Osr Holdings, Inc.较为活跃,换手率分别为400.94%、280.75%、39.75%,振幅较大的相关个股有Pasithea Therapeutics Corp.、Enlivex Therapeutics Ltd.、Bioatla, Inc.,振幅分别为30.35%、18.96%、16.60%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223327a4b753d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223327a4b753d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGNDZ","LGNYZ","LU0566484027.USD","LGNZZ","LU1559883803.SGD","LGND","BK4007","LGNXZ","IE0009354923.USD"],"gpt_icon":0},{"id":"1161851018","title":"Ligand Pharmaceuticals第三季度每股收益为5.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1161851018","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161851018?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:59","pubTimestamp":1763571549,"startTime":"0","endTime":"0","summary":"11月6日消息 - Ligand Pharmaceuticals第三季度营业收入为5493.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","BK4139","LGND","LU0566484027.USD","IE0009354923.USD"],"gpt_icon":0},{"id":"1111759520","title":"历史数据显示,下周这些美股公司公布的财报往往会超出预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1111759520","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111759520?lang=zh_cn&edition=full","pubTime":"2025-10-31 11:14","pubTimestamp":1761880440,"startTime":"0","endTime":"0","summary":"通常来说,如果公司公布的盈利或收入高于华尔街分析师的普遍预期,其股价往往会在财报发布后迎来上涨。媒体参考了Bespoke Investment Group 的数据,筛选出那些历来有较高概率超出预期并在财报后上涨的股票。这家网络设备制造商在过去每次财报中都100% 超出盈利预期,且财报发布后的首个交易日股价平均上涨 1.6%。$Shopify Inc$ 是另一家将在下周公布财报且有历史超预期纪录的公司。这家电子商务及销售点系统公司有 85% 的时间超出盈利预期,财报后平均上涨 3.7%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/b0c14ebc2f7f5fc21f630e61dda45b36","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b0c14ebc2f7f5fc21f630e61dda45b36"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"418b6a29038f2143bcaf874c508fb15e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"历史数据显示,下周这些美股公司公布的财报往往会超出预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LOPE","KRNT","SHOP","CSGS","TREX","LGND","PAYC","WING","MTD","ANET"],"gpt_icon":1},{"id":"1117375496","title":"Ligand Pharmaceuticals合作伙伴Sq Innovation获得FDA批准,推出用于心衰患者水肿居家治疗的Lasix® Onyu","url":"https://stock-news.laohu8.com/highlight/detail?id=1117375496","media":"美股速递","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117375496?lang=zh_cn&edition=full","pubTime":"2025-10-09 19:18","pubTimestamp":1760008722,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals的合作伙伴Sq Innovation宣布,其产品Lasix® Onyu已获得美国食品药品监督管理局(FDA)的批准。该产品是一款专门针对心力衰竭患者水肿症状的居家治疗方案。\n这一批准标志着心衰患者在管理水肿症状方面迈出了重要一步,使患者能够在家中便捷地接受治疗,无需频繁前往医疗机构。Lasix® Onyu为心力衰竭患者提供了更加灵活和便利的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0566484027.USD","LU1559883803.SGD","LGND","BK4007"],"gpt_icon":0},{"id":"1198835935","title":"ARECOR THERAPEUTICS PLC宣布与Ligand Pharmaceuticals Inc.达成版税融资协议,筹资上限达1100万美元且不摊薄股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1198835935","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198835935?lang=zh_cn&edition=full","pubTime":"2025-09-25 14:13","pubTimestamp":1758780810,"startTime":"0","endTime":"0","summary":"ARECOR THERAPEUTICS PLC宣布与Ligand Pharmaceuticals Inc.达成版税融资协议,该协议将为公司筹集最多1100万美元的非稀释性资本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LGND","LU0566484027.USD","LU1559883803.SGD","BK4139","BK5083","AREC.UK"],"gpt_icon":0},{"id":"1126660147","title":"异动解读 | 利根制药股价盘中大涨5.29%,4亿美元可转债发行引发投资者热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1126660147","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126660147?lang=zh_cn&edition=full","pubTime":"2025-08-12 21:44","pubTimestamp":1755006249,"startTime":"0","endTime":"0","summary":"周二盘中,Ligand Pharmaceuticals Inc.股价大幅上涨5.29%,引发市场广泛关注。这一涨幅很可能与公司最新宣布的融资计划有关。据悉,Ligand Pharmaceuticals于周一晚间宣布成功定价4亿美元的可转换债券,债券将于2030年到期。公司计划将部分募集资金用于可转换债券对冲交易和回购某些债券购买的股票,剩余资金将用于一般企业用途,包括投资互补性业务和产品。据LSEG数据显示,七家覆盖该股的券商均给予\"买入\"或更高评级,目标价中位数为162美元。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LGND"],"gpt_icon":0},{"id":"1177365747","title":"异动解读 | Ligand Pharmaceuticals盘中大跌8%,拟发行4亿美元可转债","url":"https://stock-news.laohu8.com/highlight/detail?id=1177365747","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177365747?lang=zh_cn&edition=full","pubTime":"2025-08-11 22:04","pubTimestamp":1754921048,"startTime":"0","endTime":"0","summary":"周一盘中,Ligand Pharmaceuticals Inc.股价大幅下跌8.04%,引发投资者关注。据报道,Ligand Pharmaceuticals宣布计划以私募方式发行4亿美元2030年到期的可转换债券。公司表示,部分募集资金将用于支付可转换债券对冲交易,并将最多3000万美元用于回购某些债券购买的股票。可转换债券的发行通常会导致股价下跌,主要是因为投资者担心现有股份可能被稀释。尽管Ligand Pharmaceuticals的股价今年累计上涨40%,但这一融资计划显然引发了市场的担忧。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LGND"],"gpt_icon":0},{"id":"2558665030","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速下挫6.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558665030","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558665030?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:32","pubTimestamp":1754919168,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时32分,Ligand Pharmaceuticals Incorporated股票出现异动,股价急速跳水6.79%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体跌幅为0.46%。其相关个股中,Equillium, Inc.、Entero Therapeutics Inc.、Salarius Pharmaceuticals, Inc.涨幅较大,Entero Therapeutics Inc.、Equillium, Inc.、Io Biotech, Inc.较为活跃,换手率分别为1783.61%、218.09%、76.89%,振幅较大的相关个股有Entero Therapeutics Inc.、Equillium, Inc.、Io Biotech, Inc.,振幅分别为33.16%、32.31%、11.88%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213248a6dfb8a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811213248a6dfb8a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGND","LGNXZ","LGNDZ","BK4139","LGNZZ","LU1559883803.SGD","BK4007","LGNYZ","LU0566484027.USD"],"gpt_icon":0},{"id":"2557302206","title":"Ligand Pharmaceuticals Incorporated盘中异动 股价大涨5.08%报142.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557302206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557302206?lang=zh_cn&edition=full","pubTime":"2025-08-07 03:59","pubTimestamp":1754510364,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日03时59分,Ligand Pharmaceuticals Incorporated股票出现异动,股价快速拉升5.08%。截至发稿,该股报142.01美元/股,成交量20.0118万股,换手率1.04%,振幅7.25%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为0.01%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080703592497381350&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080703592497381350&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LGND","LGNYZ","LGNXZ","LU0566484027.USD","LGNZZ","LGNDZ","BK4139","LU1559883803.SGD"],"gpt_icon":0},{"id":"2551512985","title":"Ligand Pharmaceuticals Incorporated盘中异动 股价大涨5.25%报130.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551512985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551512985?lang=zh_cn&edition=full","pubTime":"2025-07-16 22:48","pubTimestamp":1752677282,"startTime":"0","endTime":"0","summary":"北京时间2025年07月16日22时48分,Ligand Pharmaceuticals Incorporated股票出现异动,股价急速拉升5.25%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为1.20%。其相关个股中,知临集团、Abpro Holdings Inc C/Wts 12/11/2029 、Briacell Therapeutics Corp C/Wts 26/02/2026涨幅较大,Qualigen Therapeutics, Inc.、知临集团、Tnf Pharmaceuticals, Inc.较为活跃,换手率分别为2641.71%、1247.47%、1026.85%,振幅较大的相关个股有知临集团、Briacell Therapeutics Corp C/Wts 26/02/2026、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ,振幅分别为334.61%、77.54%、77.02%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716224803a6adc0a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716224803a6adc0a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNYZ","LGNDZ","LGNXZ","LU1559883803.SGD","BK4139","LU0566484027.USD","BK4007","LGNZZ","LGND"],"gpt_icon":0},{"id":"2550656843","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550656843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550656843?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:02","pubTimestamp":1752069759,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时02分,Ligand Pharmaceuticals Incorporated股票出现异动,股价快速上涨5.68%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为1.28%。其相关个股中,Calidi Biotherapeutics, Inc.、Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 、Prokidney Corp.涨幅较大,Calidi Biotherapeutics, Inc.、Kazia Therapeutics Limited、Mustang Bio, Inc.较为活跃,换手率分别为759.14%、647.05%、480.19%,振幅较大的相关个股有Lixte Biotechnology Holdings Inc C/Wts 30/11/2025 、Calidi Biotherapeutics, Inc.、Prokidney Corp.,振幅分别为112.02%、59.70%、48.79%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709220240953c3bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709220240953c3bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNDZ","LU1559883803.SGD","BK4007","LGNZZ","LGND","BK4139","LU0566484027.USD","LGNXZ","LGNYZ"],"gpt_icon":0},{"id":"2518275372","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275372","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518275372?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:02","pubTimestamp":1741615340,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时02分,Ligand Pharmaceuticals Incorporated股票出现波动,股价快速下挫5.12%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为0.02%。其相关个股中,Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大,Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃,换手率分别为668.89%、329.35%、92.62%,振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.,振幅分别为41.36%、40.24%、28.59%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220221abf30860&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220221abf30860&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LGND","LGNDZ","BK4139","LGNYZ","LGNXZ","LGNZZ","LU1559883803.SGD","LU0566484027.USD"],"gpt_icon":0},{"id":"2517145817","title":"Ligand Pharmaceuticals Incorporated2024财年实现净利润-4.03百万美元,同比减少107.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145817","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517145817?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363235,"startTime":"0","endTime":"0","summary":"3月8日,Ligand Pharmaceuticals Incorporated公布财报,公告显示公司2024财年净利润为-4.03百万美元,同比减少107.49%;其中营业收入为1.67亿美元,同比增加27.48%,每股基本收益为-0.22美元。从资产负债表来看,Ligand Pharmaceuticals Incorporated总负债1.11亿美元,其中短期债务1.29百万美元,资产负债比为8.49,流动比率为0.09。机构评级:截至2025年3月8日,当前有7家机构对Ligand Pharmaceuticals Incorporated目标价做出预测,其中目标均价为144.86美元,其中最低目标价为125.00美元,最高目标价为160.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000045a2647e57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000045a2647e57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNYZ","LGNDZ","LGNXZ","LGND","LGNZZ"],"gpt_icon":0},{"id":"2516630569","title":"Ligand Pharmaceuticals Incorporated盘中异动 股价大跌5.06%报116.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630569","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630569?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:15","pubTimestamp":1741014937,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时15分,Ligand Pharmaceuticals Incorporated股票出现波动,股价快速下挫5.06%。截至发稿,该股报116.05美元/股,成交量1.4762万股,换手率0.08%,振幅4.65%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体跌幅为0.09%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032315379637b830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032315379637b830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0566484027.USD","LGND","LGNZZ","LGNXZ","LU1559883803.SGD","LGNYZ","BK4007","BK4139","LGNDZ"],"gpt_icon":0},{"id":"1195157340","title":"异动解读 | Ligand Pharmaceuticals盘中股价剧涨5.07% 公司业绩表现亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1195157340","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195157340?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:26","pubTimestamp":1740763592,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.(LGND)股价今日盘中大涨5.07%,引起市场关注。消息显示,这家生物制药公司最新财报业绩表现优异,推动其股价上涨。\n\n公司最新披露的财报数据显示,Ligand Pharmaceuticals上一季度实现营收5181万美元,毛利4111万美元。尽管出现小幅净亏损,但公司营收和毛利润均保持较高水平,体现出公司运营获利能力不俗。\n\n此外,机构对该公司前景也持看好态度。目前有7家机构给予Ligand Pharmaceuticals股票\"买入\"评级,评级比例高达100%,反映市场对其长期增长信心充足。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Ligand Pharmaceuticals盘中股价剧涨5.07% 公司业绩表现亮眼","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LGND"],"gpt_icon":0},{"id":"2516372598","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.07%报121.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516372598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516372598?lang=zh_cn&edition=full","pubTime":"2025-03-01 01:07","pubTimestamp":1740762443,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日01时07分,Ligand Pharmaceuticals Incorporated股票出现异动,股价大幅拉升5.07%。截至发稿,该股报121.54美元/股,成交量3.4864万股,换手率0.18%,振幅4.47%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为0.47%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301010723a2582793&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301010723a2582793&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNDZ","LGNYZ","LGND","LU1559883803.SGD","BK4139","LGNZZ","LGNXZ","BK4007","LU0566484027.USD"],"gpt_icon":0},{"id":"1167626655","title":"异动解读 | LGND 2024年Q4财报超预期,股价盘中大涨6.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167626655","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167626655?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:32","pubTimestamp":1740670354,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Inc.今日盘中股价大涨6.32%,引发市场广泛关注。根据相关报道,LGND公司2024年第四季度财报数据超出分析师预期,成为推动股价上涨的主因。总的来说,LGND今日股价大涨与其财报业绩表现优异有直接关系,业绩超预期成为助推股价上行的主导力量。投资者乐观看好该公司未来发展前景,推动了LGND股价在盘中出现大涨行情。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LGND"],"gpt_icon":0},{"id":"2514810543","title":"Ligand Pharmaceuticals Incorporated盘中异动 大幅上涨5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514810543","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514810543?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:23","pubTimestamp":1740669808,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分,Ligand Pharmaceuticals Incorporated股票出现波动,股价快速拉升5.18%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体涨幅为1.14%。其相关个股中,Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大,Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃,换手率分别为885.78%、177.60%、104.84%,振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd,振幅分别为74.16%、43.51%、34.80%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232328a256879a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232328a256879a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0566484027.USD","LGNXZ","BK4139","LGNZZ","BK4007","LGNDZ","LGNYZ","LU1559883803.SGD","LGND"],"gpt_icon":0},{"id":"1191904562","title":"Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19,销售额$4281万 超过预估的$3902万","url":"https://stock-news.laohu8.com/highlight/detail?id=1191904562","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191904562?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:08","pubTimestamp":1740658089,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals公布季度每股收益为$1.27,超过分析师共识预估的$1.19,高出6.72%。相比去年同期每股收益$1.38,下降了7.97%。以上内容来自Benzinga Earnings专栏,原文如下:Ligand Pharmaceuticals reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.19 by 6.72 percent. This is a 7.97 percent decrease over earnings of $1.38 per share from the same period last year. The company reported quarterly sales of $42.81 million which beat the analyst consensus estimate of $39.02 million by 9.71 percent. This is a 52.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ligand Pharmaceuticals 2024年第四季度调整后每股收益$1.27 超过预估的$1.19,销售额$4281万 超过预估的$3902万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGND"],"gpt_icon":0},{"id":"2511110836","title":"Ligand Pharmaceuticals Incorporated盘中异动 急速上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511110836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511110836?lang=zh_cn&edition=full","pubTime":"2025-02-15 03:40","pubTimestamp":1739562048,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日03时40分,Ligand Pharmaceuticals Incorporated股票出现波动,股价急速上涨5.22%。Ligand Pharmaceuticals Incorporated股票所在的生物技术行业中,整体跌幅为0.60%。其相关个股中,Moleculin Biotech, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Allogene Therapeutics, Inc.涨幅较大,Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃,换手率分别为3111.92%、792.89%、621.89%,振幅较大的相关个股有Lexaria Bioscience Corp C/Wts 14/01/2026 、Moleculin Biotech, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 ,振幅分别为74.35%、71.65%、66.45%。Ligand Pharmaceuticals Incorporated公司简介:Ligand Pharmaceuticals是一家专注于药物生成科技开发和收购的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150340489885ce50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150340489885ce50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGNDZ","LGNXZ","LGNYZ","LGND","LGNZZ","LU0566484027.USD","LU1559883803.SGD","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ligand.com","stockEarnings":[{"period":"1week","weight":0.0445},{"period":"1month","weight":-0.0397},{"period":"3month","weight":0.1603},{"period":"6month","weight":0.6825},{"period":"1year","weight":0.6498},{"period":"ytd","weight":0.8001}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ligand Pharmaceuticals Incorporated于1987年在特拉华州注册,是一家生物制药公司。公司商业模式为,开发或收购能产生收益的资产,将其融合到精益企业的成本结构中。公司的目标是创造可持续盈利的业务以生成股东价值。由于公司的商业模式是基于与其他制药公司合作,商业化利用并销售资产,因此公司不少收入来自合作伙伴提供的相关使用费。公司认识到了制药行业药物重制的重要性,2011年将CAPTISOL项目加入到技术投资中。CAPTISOL是一个功能强大的配方技术,拥有5个美国食品药品管理局批准的产品,包括Pfizer公司的VFEND IV和Baxter International公司的Nexterone,以及其他一些在临床阶段投入使用的合作伙伴项目。与同行的其他公司相比,公司已经组建了一个最大的行业多元化资产组合,在未来能产生显著的收益。资产组合中发展的治疗方案可以解决许多尚未得到解决的医疗需求缺口,包括肝炎、肌肉萎缩、老年痴呆症、血脂异常、糖尿病、贫血、哮喘、类风湿关节炎、和骨质疏松症。","yearOnYearQuotes":[{"month":1,"riseRate":0.433333,"avgChangeRate":0.005465},{"month":2,"riseRate":0.466667,"avgChangeRate":0.017615},{"month":3,"riseRate":0.533333,"avgChangeRate":0.02916},{"month":4,"riseRate":0.533333,"avgChangeRate":0.006759},{"month":5,"riseRate":0.466667,"avgChangeRate":0.022371},{"month":6,"riseRate":0.645161,"avgChangeRate":0.058881},{"month":7,"riseRate":0.483871,"avgChangeRate":-0.009004},{"month":8,"riseRate":0.548387,"avgChangeRate":-0.017853},{"month":9,"riseRate":0.387097,"avgChangeRate":0.004496},{"month":10,"riseRate":0.6,"avgChangeRate":0.000952},{"month":11,"riseRate":0.5,"avgChangeRate":0.026577},{"month":12,"riseRate":0.645161,"avgChangeRate":0.047313}],"exchange":"NASDAQ","name":"Ligand Pharmaceuticals Inc.","nameEN":"Ligand Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ligand Pharmaceuticals Inc.(LGND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ligand Pharmaceuticals Inc.(LGND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ligand Pharmaceuticals Inc.,LGND,Ligand Pharmaceuticals Inc.股票,Ligand Pharmaceuticals Inc.股票老虎,Ligand Pharmaceuticals Inc.股票老虎国际,Ligand Pharmaceuticals Inc.行情,Ligand Pharmaceuticals Inc.股票行情,Ligand Pharmaceuticals Inc.股价,Ligand Pharmaceuticals Inc.股市,Ligand Pharmaceuticals Inc.股票价格,Ligand Pharmaceuticals Inc.股票交易,Ligand Pharmaceuticals Inc.股票购买,Ligand Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ligand Pharmaceuticals Inc.(LGND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ligand Pharmaceuticals Inc.(LGND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}